Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension

By sjmartinez • October 11, 2022

Didriksen H, Molberg Ø, Mehta A, Jordan S, Palchevskiy V, Fretheim H, Gude E, Ueland T, Brunborg C, Garen T, Midtvedt Ø, Andreassen AK, Lund-Johansen F, Distler O, Belperio J, Hoffmann-Vold AM. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. Front Immunol. 2022 Sep 23;13:991743. doi: 10.3389/fimmu.2022.991743. PMID: 36211384; PMCID: PMC9541617.

Tags: Anti-CCL21, CCL21, ELISA Enzyme-linked immunosorbent assay, Luminex (xMAP) method, Publications, pulmonary arteria hypertension, Pulmonary, Critical Care & Sleep Medicine, systemic sclerosis

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Leiva O, Liu O, Kanelidis A, Swat S, Gozdecki L, Belkin M, Grinstein J, Kalantari S, Kim G, DeCara J, Chung B, Patel A, Odenike[...]

Self-Reported Resilience During the COVID-19 Pandemic

Ogungbe O, Wang T, Balte PP, Slone SE, Meyer D, Allen NB, Buhr RG, Hirsch JA, Hinckley Stukovsky K, Kucharska-Newton A, Gabriel KP, Regan EA,[...]

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma

Armand P, Zinzani PL, Timmerman JM, Johnson NA, Lavie D, Thiagarajan K, Topp B, Pillai PM, Herrera AF. Estimating efficacy of favezelimab plus pembrolizumab relative[...]